Article Text

Download PDFPDF
Is incentivising stroke prevention therapy in atrial fibrillation the key?

Statistics from Altmetric.com

Footnotes

  • Contributors RKS wrote the first draft of the editorial, and both authors edited the overall manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests JAE has received research support and honoraria from BMS/Pfizer and Bayer related to oral anticoagulation in patients with atrial fibrillation and served on the Steering Committee for ARISTOTLE. RKS has no relevant disclosures.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles